Please ensure Javascript is enabled for purposes of website accessibility

Why AVEO Oncology Stock Is Crashing Today

By Keith Speights - Updated Apr 24, 2019 at 11:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bad news from the FDA caused investors to head for the hills.

What happened

Shares of AVEO Oncology (AVEO -4.38%) had crashed 58.6% as of 11:33 a.m. EST on Thursday. The biotech announced that based on preliminary overall survival rate data from its phase 3 Tivo-3 clinical study, it wouldn't file for regulatory approval of lead candidate Fotivda in treating advanced renal cell carcinoma (RCC). AVEO stated that the U.S. Food and Drug Administration (FDA) recommended against filing for approval because the preliminary data didn't address concerns the agency has raised in the past about the experimental drug. 

So what

This was strike two for AVEO with Fotivda. The FDA rejected approval of the drug back in 2013 because of safety concerns. AVEO had hoped that the Tivo-3 study would put those concerns to rest, but that's clearly not going to happen now.

Businessman watching red line chart go through the floor

Image source: Getty Images.

The problem with the phase 3 study results was that the preliminary overall survival hazard ratio for patients taking Fotivda was 1.12. The hazard ratio indicates the likelihood of death for patients receiving a drug compared to that of a control group. Any hazard ratio above 1.0 isn't good news since it means that patients taking a therapy are more likely to die than other patients are.

Even worse for AVEO is that the overall survival hazard ratio had increased from what the company announced in November. At the time, AVEO reported a preliminary hazard ratio of 1.06. However, the biotech subsequently "identified the survival status of a group of patients that were previously lost to follow up." 

AVEO's decision to back off from filing for FDA approval for Fotivda means that a great degree of uncertainty exists about whether or not it will ever be able to market the drug in the U.S. However, Fotvida has gained regulatory approval in the European Union, Norway, and Iceland.  

Now what

AVEO stated that it now plans to designate the overall survival analysis from the Tivo-3 study, scheduled to be announced in August 2019, as interim results. However, the company expects to evaluate more mature data in the fourth quarter of 2019. AVEO CEO Michael Bailey expressed hope that this later data could "translate into an improved hazard ratio."

Cash could be a problem in the meantime for AVEO, though. The biotech's share price sank in December over worries about its cash position. With a delay in filing for Fotivda, AVEO will likely have to raise more money. That might mean issuing new shares, which would cause the value of existing shares to fall even more.

Check out all our earnings call transcripts.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AVEO Pharmaceuticals, Inc. Stock Quote
AVEO Pharmaceuticals, Inc.
$6.12 (-4.38%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.